Parallel evolution and local differentiation in quinolone resistance in Pseudomonas aeruginosa

Microbiology

Volumn 157, Issue 4, 2011, Pages 937-944

  Wong, Alex ^a   Kassen, Rees ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE IV; QUINOLONE;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; EVOLUTION; GENE MUTATION; MEXR GENE; NFXB GENE; NONHUMAN; PARALLEL EVOLUTION; PARC GENE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CYSTIC FIBROSIS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA-BINDING PROTEINS; DRUG RESISTANCE, BACTERIAL; EVOLUTION, MOLECULAR; HUMANS; MUTATION, MISSENSE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUINOLONES; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 79953729362     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/mic.0.046870-0     Document Type: Review

References (55)

1. Albert, T. J., Dailidiene, D., Dailide, G., Norton, J. E., Kalia, A., Richmond, T. A., Molla, M., Singh, J., Green, R. D. & Berg, D. E. (2005). Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori. Nat Methods 2, 951-953.
2. Andersson, D. I. (2006). The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 9, 461-465.
3. Bagel, S., Hüllen, V., Wiedemann, B. & Heisig, P. (1999). Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother 43, 868-875.
4. Bell, M. A. & Foster, S. A. (1994). The Evolutionary Biology of the Threespine Stickleback. Oxford: Oxford University Press.
5. Björkman, J., Nagaev, I., Berg, O. G., Hughes, D. & Andersson, D. I. (2000). Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287, 1479-1482.
6. Breidenstein, E. B. M., Khaira, B. K., Wiegand, I., Overhage, J. & Hancock, R. E. (2008). Complex ciprofloxacin resistome revealed by screening a Pseudomonas aeruginosa mutant library for altered susceptibility. Antimicrob Agents Chemother 52, 4486-4491.
7. Brown, S. A., Palmer, K. L. & Whiteley, M. (2008). Revisiting the host as a growth medium. Nat Rev Microbiol 6, 657-666.
8. Cambau, E., Perani, E., Dib, C., Petinon, C., Trias, J. & Jarlier, V. (1995). Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother 39, 2248-2252.
9. CDC (2010). National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2008. Atlanta, GA: Centers For Disease Control.
10. Chen, F. J. & Lo, H. J. (2003). Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect 36, 1-9.
11. Corey, M. & Farewell, V. (1996). Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 143, 1007-1017.
12. D'Argenio, D. A., Wu, M., Hoffman, L. R., Kulasekara, H. D., Déziel, E., Smith, E. E., Nguyen, H., Ernst, R. K., Larson Freeman, T. J. & other authors (2007). Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol 64, 512-533.
13. Dean, A. M. (1995). A molecular investigation of genotype by environment interactions. Genetics 139, 19-33.
14. Diver, J. M., Schollaardt, T., Rabin, H. R., Thorson, C. & Bryan, L. E. (1991). Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother 35, 1538-1546.
15. Emmerson, A. M. & Jones, A. M. (2003). The quinolones: decades of development and use. J Antimicrob Chemother 51 (Suppl. 1), 13-20.
16. Fung-Tomc, J., Kolek, B. & Bonner, D. P. (1993). Ciprofloxacininduced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 37, 1289-1296.
17. Government of Canada (2007). Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS). Guelph, ON: Public Health Agency of Canada.
18. Halligan, D. L. & Keightley, P. D. (2009). Spontaneous mutation accumulation studies in evolutionary genetics. Annu Rev Ecol Evol Syst 40, 151-172.
19. Hancock, R. E. W. (1998). Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 27 (Suppl. 1), S93-S99.
20. Hassett, D. J., Sutton, M. D., Schurr, M. J., Herr, A. B., Caldwell, C. C. & Matu, J. O. (2009). Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends Microbiol 17, 130-138.
21. Hedrick, P. W. (2006). Genetic polymorphism in heterogeneous environments: the age of genomics. Annu Rev Ecol Evol Syst 37, 67-93.
22. Henrichfreise, B., Wiegand, I., Pfister, W. & Wiedemann, B. (2007). Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 51, 4062-4070.
23. Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S. & Ciofu, O. (2010). Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35, 322-332.
24. Hoogkamp-Korstanje, J. A., van Oort, H. J., Schipper, J. J. & van der Wal, T. (1984). Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens. J Antimicrob Chemother 14, 641-645.
25. Jacoby, G. A. (2005). Mechanisms of resistance to quinolones. Clin Infect Dis 41 (Suppl. 2), S120-S126.
26. Jakics, E. B., Iyobe, S., Hirai, K., Fukuda, H. & Hashimoto, H. (1992). Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 36, 2562-2565.
27. Joukhadar, C., Dehghanyar, P., Traunmüller, F., Sauermann, R., Mayer-Helm, B., Georgopoulos, A. & Müller, M. (2005). Increase of microcirculatory blood flow enhances penetration of ciprofloxacin into soft tissue. Antimicrob Agents Chemother 49, 4149-4153.
28. Kassen, R. & Bataillon, T. (2006). Distribution of fitness effects among beneficial mutations before selection in experimental populations of bacteria. Nat Genet 38, 484-488.
29. Kugelberg, E., Löfmark, S., Wretlind, B. & Andersson, D. I. (2005). Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob Chemother 55, 22-30.
30. Kureishi, A., Diver, J. M., Beckthold, B., Schollaardt, T. & Bryan, L. E. (1994). Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob Agents Chemother 38, 1944-1952.
31. Luria, S. E. & Delbrück, M. (1943). Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28, 491-511.
32. Martínez-Martínez, L., Pascual, A. & Jacoby, G. A. (1998). Quinolone resistance from a transferable plasmid. Lancet 351, 797-799.
33. Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H. & Nishino, T. (2000). Substrate specificities of MexAB-OprM, MexCDOprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44, 3322-3327.
34. Mathee, K., Narasimhan, G., Valdes, C., Qiu, X., Matewish, J. M., Koehrsen, M., Rokas, A., Yandava, C. N., Engels, R. & other authors (2008). Dynamics of Pseudomonas aeruginosa genome evolution. Proc Natl Acad Sci U S A 105, 3100-3105.
35. Nöllmann, M., Crisona, N. J. & Arimondo, P. B. (2007). Thirty years of Escherichia coli DNA gyrase: from in vivo function to single-molecule mechanism. Biochimie 89, 490-499.
36. Palmer, K. L., Aye, L. M. & Whiteley, M. (2007). Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol 189, 8079-8087.
37. Pedersen, S. S., Jensen, T. & Hvidberg, E. F. (1987). Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. J Antimicrob Chemother 20, 575-583.
38. Perron, G. G., Hall, A. R. & Buckling, A. (2010). Hypermutability and compensatory adaptation in antibiotic-resistant bacteria. Am Nat 176, 303-311.
39. Piddock, L. J. (1999). Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58 (Suppl. 2), 11-18.
40. Poole, K. (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56, 20-51.
41. Rau, M. H., Hansen, S. K., Johansen, H. K., Thomsen, L. E., Workman, C. T., Nielsen, K. F., Jelsbak, L., Høiby, N., Yang, L. & Molin, S. (2010). Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. EnvironMicrobiol 12, 1643-1658.
42. Remold, S. K. & Lenski, R. E. (2001). Contribution of individual random mutations to genotype-by-environment interactions in Escherichia coli. Proc Natl Acad Sci U S A 98, 11388-11393.
43. Rosenfeld, M., Davis, R., Fitz Simmons, S., Pepe, M. & Ramsey, B. (1997). Gender gap in cystic fibrosis mortality. Am J Epidemiol 145, 794-803.
44. Rowen, D. W. & Deretic, V. (2000). Membrane-to-cytosol redistribution of ECF sigma factor AlgU and conversion to mucoidy in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Mol Microbiol 36, 314-327.
45. Schoeffler, A. J. & Berger, J. M. (2005). Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem Soc Trans 33, 1465-1470.
46. Shorr, A. F. (2009). Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 37, 1463-1469.
47. Sissi, C. & Palumbo, M. (2010). In front of and behind the replication fork: bacterial type IIA topoisomerases. Cell Mol Life Sci 67, 2001-2024.
48. Stephenson, A. (2008). Canadian Cystic Fibrosis Patient Data Registry Report 2008. Toronto: Canadian Cystic Fibrosis Foundation.
49. Strahilevitz, J., Jacoby, G. A., Hooper, D. C. & Robicsek, A. (2009). Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 22, 664-689.
50. Tamae, C., Liu, A., Kim, K., Sitz, D., Hong, J., Becket, E., Bui, A., Solaimani, P., Tran, K. P. & other authors (2008). Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. J Bacteriol 190, 5981-5988.
51. Ward, H., Perron, G. G. & Maclean, R. C. (2009). The cost of multiple drug resistance in Pseudomonas aeruginosa. J Evol Biol 22, 997-1003.
52. Winter, J. & Sweeney, G. (1991). Reproducibility of the measurement of ciprofloxacin concentration in bronchial mucosa. J Antimicrob Chemother 27, 329-333.
53. Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U., Cekici, A., Meyer, K. C., Birrer, P., Bellon, G., Berger, J. & other authors (2002). Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109, 317-325.
54. Zhang, L. & Mah, T.-F. (2008). Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol 190, 4447-4452.
55. Zhou, J., Dong, Y., Zhao, X., Lee, S., Amin, A., Ramaswamy, S., Domagala, J., Musser, J. M. & Drlica, K. (2000). Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 182, 517-525.